GISSI-2 and the heparin controversy.
White
H D
HD
Green Lane Hospital, Auckland, New Zealand.
D017023:Coronary Angiography; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006493:Heparin / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality / Q000503:physiopathology; D010314:Partial Thromboplastin Time; D013300:Streptokinase / Q000627:therapeutic use; D015912:Thrombolytic Therapy; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000378:metabolism / Q000627:therapeutic use; D014654:Vascular Patency / Q000187:drug effects* / Q000502:physiology
D006493:Heparin; D013300:Streptokinase; D010959:Tissue Plasminogen Activator